AnaptysBio
ANAB
134 hedge funds and large institutions have $2.53B invested in AnaptysBio in 2018 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 43 increasing their positions, 43 reducing their positions, and 18 closing their positions.
106% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 18
16% more funds holding
Funds holding: 116 → 134 (+18)
6% more capital invested
Capital invested by funds: $2.39B → $2.53B (+$139M)
1.07% more ownership
Funds ownership: 101.17% → 102.24% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 7 → 7 (0)
0% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 43
25% less call options, than puts
Call options by funds: $40.7M | Put options by funds: $54.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$56.6M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$51.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$38.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$35.2M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$34.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$58.5M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$56.5M |
| 3 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$40.1M |
| 4 |
Morgan Stanley
New York
|
-$32.2M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$23.5M |
ANAB Hedge Fund Activity: Q1 2018 in Review
134 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q1 2018, worth a combined $2.53B — up 5.8% from $2.39B a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ANAB positions and 18 closed out — a net gain of 19 holders — while 43 added to existing stakes and 43 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $56.6M. The largest seller was Perceptive Advisors, cutting an estimated $58.5M.
- 134 institutional investors held AnaptysBio (ANAB) as of Q1 2018, up from 116 in Q4 2017.
- Funds reported $2.53B of AnaptysBio stock for Q1 2018, up 5.8% quarter-over-quarter.
- 37 funds opened new AnaptysBio positions in Q1 2018 and 18 closed out, a net change of +19 holders.
- The largest AnaptysBio buyer in Q1 2018 was Janus Henderson Group, an estimated $56.6M added.
- The largest AnaptysBio seller in Q1 2018 was Perceptive Advisors, an estimated $58.5M sold.
Based on aggregated 13F filings for Q1 2018.